Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 1 · below the Ichimoku cloud · RSI 33 · MACD below its signal
None of the 29 investors followed here reported a position in CAMP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CAMP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -39.6 | 21.4 | -1.8 | -5.4 | 5.3 | -0.5 | -21.1 | 14.8 | 2.0 | -18.1 | −46.0% | ||
| 2025 | -7.9 | 2.1 | -18.5 | -55.8 | 11.9 | -26.8 | 12.4 | -6.7 | 97.4 | 38.7 | -8.7 | 61.3 | +17.4% |
| 2024 | -54.9 | 9.0 | −50.9% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 30, 2026 | Gold KellyChief Financial Officer | Purchase at price 3.96 per share. | 10K | $39.60K |
| Aug 26, 2026 | Schwab Andrew J.Director | Sale at price 4.04 per share. | 400K | $1.62M |
| Aug 23, 2026 | Schwab Andrew J.Director | Sale at price 4.50 per share. | 10 | $45 |
| Aug 20, 2026 | Schwab Andrew J.Director | Sale at price 4.50 - 4.76 per share. | 191.9K | $879.72K |
| Aug 18, 2026 | Tardiff DanielOfficer | Sale at price 4.76 per share. | 1.7K | $8.27K |
| Aug 2, 2026 | Young Richard ADirector | Purchase at price 4.21 per share. | 16.4K | $68.95K |
| Aug 2, 2026 | Maricich Yuri M.D.Officer | Purchase at price 4.21 per share. | 6.6K | $27.58K |
| Aug 2, 2026 | Mandel-Brehm JoshChief Executive Officer | Purchase at price 4.21 per share. | 6.6K | $27.58K |
| Aug 2, 2026 | Gold KellyChief Financial Officer | Purchase at price 4.21 per share. | 6.6K | $27.58K |
| Sep 10, 2025 | Young Richard ADirector | Purchase at price 2.78 per share. | 15.2K | $42.12K |
| Sep 10, 2025 | Nashat Amir H.Director and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.79 per share. | 1.31M | $3.65M |
| Sep 10, 2025 | Polaris Management Co. Vii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.79 per share. | 1.31M | $3.65M |
| Sep 10, 2025 | Maricich Yuri M.D.Officer | Purchase at price 2.79 per share. | 6.1K | $16.91K |
| Sep 10, 2025 | 5am Partners Vi, LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 2.78 per share. | 2.94M | $8.18M |
| Sep 10, 2025 | Mandel-Brehm JoshChief Executive Officer | Purchase at price 2.79 per share. | 6.1K | $16.91K |
| Sep 10, 2025 | Gold KellyChief Financial Officer | Purchase at price 2.79 per share. | 6.1K | $16.91K |
| Sep 10, 2025 | Schwab Andrew J.Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 2.78 per share. | 2.94M | $8.18M |
| Oct 14, 2024 | Holtzman Steven HDirector | — | 8.9K | — |
| Oct 14, 2024 | Schwab Andrew J.Director and Beneficial Owner of more than 10% of a Class of Security | — | 2.02M | — |
| Oct 14, 2024 | Young Richard ADirector | — | 8.9K | — |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Buy / hold / sell counts